Research progress on engineered tumor whole-cell vaccines
10.12206/j.issn.2097-2024.202402014
- VernacularTitle:工程化肿瘤全细胞疫苗研究进展
- Author:
Weifan WANG
1
;
Fengze MIAO
2
;
Zongguang TAI
2
;
Quangang ZHU
2
;
Zhongjian CHEN
2
;
Cuiyun YU
3
Author Information
1. School of Pharmaceutical Science, University of South China, Hengyang 421001, China;Shanghai Skin Disease Hospital, Shanghai 200443, China.
2. Shanghai Skin Disease Hospital, Shanghai 200443, China.
3. School of Pharmaceutical Science, University of South China, Hengyang 421001, China.
- Publication Type:Reviews
- Keywords:
whole-tumor-cell vaccine;
genetic engineering strategies;
immunotherapy;
antigen;
immunogenic cell death
- From:
Journal of Pharmaceutical Practice and Service
2026;44(5):221-227
- CountryChina
- Language:Chinese
-
Abstract:
The emergence of immunotherapy has provided new optimism for cancer treatment. Tumor vaccine, a promising immunotherapy strategy, can be categorized into those with identified single or multiple antigens and those with unidentified whole-tumor antigens as their antigenic sources. Currently, mainstream tumor vaccines are still based on identified antigens. However, due to their limitations, tumor vaccines prepared based on whole tumor antigens have unique advantages. However, the low immunogenicity of whole-tumor antigen vaccines affected their clinical efficacy. To improve the immunogenicity, researchers have employed various strategies such as immunogenic death, genetic engineering modifications, cell membrane modifications, and tumor cell lysates, which demonstrated significant clinical potential. The research progress of engineering whole-cell vaccines based on tumor cells in recent years was reviewed in this paper, with a focus on their clinical progress and application prospects.
